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A 21-year-old Asian woman presented with a waxing and
waning course of low-grade fevers, malaise, pain in the small
joints of her hands, a faint facial rash, and hair loss over a
period of several weeks. Except for the findings mentioned
above, her physical exam was unremarkable. Laboratory
studies revealed leukopenia (2.5 103/ml), anemia (11.3 g/
dL), and thrombocytopenia (100 103/ml). Antibody testing
revealed positive direct antinuclear antibodies (1186 AU/ml),
positive Antistreptolysin O titer (310 IU/ml), positive
Epstein–Barr virus immunoglobulin IgG antibody
(3186 AU/ml), positive Ehrlichia chaffeensis IgM (1:60) and
IgG (1:512), and positive human granulocytic ehrlichiosis
IgG (1:512) by indirect fluorescent antibody. Of note,
IgM titers for Epstein–Barr virus and human granulocytic
ehrlichiosis were negative. Human granulocytic ehrlichiosis
testing was also negative. In the presence of multiple positive
serologies, laboratory data, and some clinical features, the
patient was presumptively treated for ehrlichiosis with a 14-
day course of doxycycline. At a 4-week follow up, repeat
Ehrlichia chaffeensis IgM and IgG titers were further elevated
(1:1024 and 1:2048, respectively) and retreatment with
minocycline was initiated. Due to drug intolerance the
patient discontinued the treatment. A urinalysis revealed 3þ
protein; 24 h urine protein measured 0.6 gm/day and in the
following week increased to 1.7 gm/day. A renal biopsy was
performed.
What is the renal biopsy likely to show?
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The Diagnosis | Class IV-G(A) lupus nephritis
Further clinical decline occurred and over the subsequent 2-
week period, her presentation met the American College of
Rheumatology criteria for a definitive diagnosis of systemic
lupus erythematosus (SLE) (positive antinuclear antibody,
positive anti-double-stranded DNA, malar rash, proteinuria,
leukopenia, thrombocytopenia, and psychosis).
Renal biopsy (Figure 1) revealed diffuse proliferative lupus
nephritis (ISN/RPS Class IV-G(A)) with activity index 10/24
and chronicity index 0/12 according to the National
Institutes of Health criteria. Focal evidence of lupus
vasculopathy was identified.
Ehrlichiosis and SLE have comparable features. Symptoms
of ehrlichiosis include severe headache, myalgias, and fever.
Confusion may also occur. Nausea, vomiting, and abdominal
pain are uncommon and mild. Symptoms of SLE include
fever, malaise, anorexia, fatigue, weight loss, myalgias,
photosensitivity, alopecia. Cognitive dysfunction, headache,
mood disorder, cerebrovascular disease, seizures, polyneuro-
pathy, anxiety, and psychosis may also occur. On exam,
patients with ehrlichiosis display a maculopapular rash and
hepatomegaly. Lymphadenopathy is observed in less than
25%. Malar rash or discoid rash and symmetrical oligoarti-
cular arthritis are seen in SLE. Lymphadenopathy is
frequently observed; however generalized lymphadenopathy
is rare. Laboratory findings in ehrlichiosis include positive
serology, thrombocytopenia, and disseminated intravascular
coagulation (in severe ehrlichiosis). In SLE, positive serology,
leukopenia, lymphopenia, anemia, and thrombocytopenia
have been well described.
Within 1 week of initiation of treatment with steroids and
mycophenolate mofetil, Ehrlichia chaffeensis titers (IgM and
IgG) were undetectable and titers to EBV IgM and IgG
decreased (0.49 and 6.83 AU/ml, respectively). Within several
weeks the patient’s SLE entered remission.
This case report illustrates the importance of recognizing
false-positive antibody titers in the presence of active SLE.1 In
addition to Ehrlichia, false-positive antibodies to the
following infectious etiologies have been reported in patients
with SLE: syphilis, Lyme disease,2 hepatitis C,3 HIV,4
cytomegalovirus,1 and the severe acute respiratory syndrome
virus.5 To our knowledge, this is the first reported association
of false-positive Ehrlichia species antibodies in patients with
SLE.
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Figure 1 | Renal biopsy showing diffuse proliferative lupus
nephritis (ISN/RPS Class IV-G(A)) with focal evidence of
lupus vasculopathy.
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